Acumen Pharmaceuticals Inc
NASDAQ:ABOS
Income Statement
Earnings Waterfall
Acumen Pharmaceuticals Inc
Income Statement
Acumen Pharmaceuticals Inc
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
4
|
4
|
4
|
4
|
4
|
|
| Revenue |
1
N/A
|
1
-16%
|
1
-12%
|
0
-69%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(9)
|
(11)
|
(12)
|
(13)
|
(20)
|
(25)
|
(32)
|
(39)
|
(45)
|
(49)
|
(52)
|
(57)
|
(61)
|
(66)
|
(77)
|
(93)
|
(114)
|
(126)
|
(144)
|
(138)
|
|
| Selling, General & Administrative |
(1)
|
(2)
|
(3)
|
(5)
|
(7)
|
(9)
|
(11)
|
(12)
|
(13)
|
(14)
|
(15)
|
(17)
|
(19)
|
(20)
|
(20)
|
(20)
|
(20)
|
(20)
|
(20)
|
(19)
|
|
| Research & Development |
(8)
|
(9)
|
(9)
|
(8)
|
(12)
|
(16)
|
(21)
|
(27)
|
(32)
|
(35)
|
(37)
|
(40)
|
(42)
|
(46)
|
(56)
|
(73)
|
0
|
(107)
|
(124)
|
(119)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(94)
|
0
|
0
|
0
|
|
| Operating Income |
(8)
N/A
|
(10)
-22%
|
(11)
-14%
|
(13)
-13%
|
(20)
-57%
|
(25)
-28%
|
(32)
-28%
|
(39)
-23%
|
(45)
-15%
|
(49)
-9%
|
(52)
-6%
|
(57)
-9%
|
(61)
-7%
|
(66)
-8%
|
(77)
-16%
|
(93)
-21%
|
(114)
-23%
|
(126)
-11%
|
(144)
-14%
|
(138)
+4%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
4
|
6
|
8
|
9
|
10
|
12
|
11
|
0
|
11
|
8
|
5
|
|
| Total Other Income |
1
|
(23)
|
(81)
|
(81)
|
(81)
|
(58)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
12
|
(0)
|
(0)
|
(0)
|
|
| Pre-Tax Income |
(7)
N/A
|
(32)
-341%
|
(92)
-184%
|
(93)
-2%
|
(101)
-8%
|
(83)
+18%
|
(32)
+62%
|
(38)
-22%
|
(43)
-12%
|
(45)
-5%
|
(47)
-3%
|
(49)
-5%
|
(52)
-7%
|
(56)
-8%
|
(65)
-17%
|
(82)
-26%
|
(102)
-24%
|
(117)
-14%
|
(137)
-17%
|
(133)
+2%
|
|
| Net Income | |||||||||||||||||||||
| Income from Continuing Operations |
(7)
|
(32)
|
(92)
|
(93)
|
(101)
|
(83)
|
(32)
|
(38)
|
(43)
|
(45)
|
(47)
|
(49)
|
(52)
|
(56)
|
(65)
|
(82)
|
(102)
|
(117)
|
(137)
|
(133)
|
|
| Net Income (Common) |
(7)
N/A
|
(32)
-341%
|
(92)
-184%
|
(93)
-2%
|
(101)
-8%
|
(83)
+18%
|
(32)
+62%
|
(38)
-22%
|
(43)
-12%
|
(45)
-5%
|
(47)
-3%
|
(49)
-5%
|
(52)
-7%
|
(56)
-8%
|
(65)
-17%
|
(82)
-26%
|
(102)
-24%
|
(117)
-14%
|
(137)
-17%
|
(133)
+2%
|
|
| EPS (Diluted) |
-0.19
N/A
|
-0.83
-337%
|
-2.37
-186%
|
-2.43
-3%
|
-5.02
-107%
|
-2.04
+59%
|
-0.77
+62%
|
-0.94
-22%
|
-1.06
-13%
|
-1.1
-4%
|
-1.13
-3%
|
-0.89
+21%
|
-1.08
-21%
|
-0.93
+14%
|
-1.09
-17%
|
-1.37
-26%
|
-1.71
-25%
|
-1.93
-13%
|
-2.27
-18%
|
-2.21
+3%
|
|